Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy - Slideshow
…
16,645$
0,75%
Echtzeit-Aktienkurs Xeris Biopharma Holdings
Bid:
Ask:
Nachrichten zur Xeris Biopharma Holdings Aktie
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
…
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take…
Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript
…
Erfolg aus der Nische: Xeris Biopharma Holdings mit kräftigem Umsatzplus dank spezieller Therapien
Xeris Biopharma Holdings ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von Therapien für Patienten mit chronischen…
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
…
Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript
…
Xeris Biopharma unveils CEO succession plan, John Shannon to lead company
Xeris Biopharma Holdings (NASDAQ:XERS) announced a CEO succession plan with John Shannon taking over from Paul Edick on August 1,…
Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript
…
Xeris Biopharma sees 1Q revenue jump on strength of product sales
Xeris Biopharma Holdings (NASDAQ:XERS) revealed a robust growth trajectory in its first quarter, with total product revenue surging 25% compared…
Xeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetes
Xeris Biopharma Holdings (NASDAQ:XERS) and Beta Bionics have announced an exclusive worldwide collaboration and license agreement aimed at revolutionizing...…
Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump
Xeris Biopharma Holdings (NASDAQ:XERS) has bolstered its financial position through the refinancing of its debt with Hayfin Capital Management LLP,…